Ocugen (OCGN) Fundamentals 2026 — Revenue Analysis | SniperIQ

.29 on the NASDAQ. This SniperIQ fundamentals page covers Ocugen's valuation, profitability (net margin -1605.2%), revenue ($4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Ocugen's market cap?

Ocugen (OCGN) has a market capitalization of approximately $437M, trading at

.29 on the NASDAQ. Market cap moves with the live share price.

What is Ocugen's P/E ratio?

Ocugen's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 71.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Ocugen?

Ocugen runs a net profit margin of -1605.2%, a gross margin of 100.0%, and an operating margin of -1483.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ocugen generate?

Ocugen reported revenue of $4M for fiscal year 2025, with net income of -$68M and earnings per share (EPS) of -0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Ocugen pay a dividend?

Ocugen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Ocugen financially healthy?

Ocugen carries a debt-to-equity ratio of 5.74x and a current ratio of 1.86x, with a market beta of 2.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ocugen a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ocugen (OCGN) the key facts are: market cap $437M, revenue $4M, 52-week range 0.931-2.725. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.